Benefits
Trial in children on antibiotics (conditional result, reported as a letter)
A double-blind randomized trial in Chinese children, published in 2023 as a short letter rather than a full research paper, tested the CMCC63516 strain during antibiotic treatment. The result was conditional rather than a clean win: how much the probiotic helped depended on the mix of bacteria already in the child's gut, with three gut species (P. copri, B. coprocola and B. plebeius) linked to a better response. Limitations: one small study, reported in letter form, different antibiotics at different hospitals, and it was done in children being treated for a medical problem, not in healthy adults. This is the only study cited on this page.
CDI gut microbiota preservation
This refers to hospital research in people being treated with vancomycin for Clostridioides difficile infection, a serious gut infection. No study on that question is listed in this page's references, so it should be read as background rather than as evidence for this probiotic. C. difficile infection can be life threatening and is treated by doctors; a probiotic is not a treatment for it.
Spore form and shelf stability
Spore-forming probiotics are generally more resistant to heat, stomach acid and bile than common Lactobacillus and Bifidobacterium products, so they usually do not need refrigeration or a special coating. That is a convenience and storage point about spores in general. It says nothing about whether the probiotic produces a health benefit, and it was not tested in the one study cited here.
A review article, not a trial (and not cited here)
A review article is described as counting 68 published papers on Bacillus licheniformis, most of them about the digestive system. That review is not listed in this page's references, and a review summarizes other people's work rather than testing anything itself. Counting papers is not the same as showing a benefit, and it does not show that this probiotic treats enteritis, colitis or diarrhea.
Bacitracin antibiotic production
In the laboratory this species makes bacitracin, an antibiotic substance that acts on certain bacteria. Whether that translates into any change in the balance of bacteria in a person's gut has not been shown by the research cited on this page, and it is not a reason to expect the product to fight an infection.
Component of multi-strain spore probiotic blends
B. licheniformis SL-307 is one of several Bacillus strains used in multi-strain spore-based probiotic blends marketed for gut health and microbiome support. Blends typically combine 4-5 spore-forming Bacillus species for complementary mechanisms (carotenoid production, antimicrobial peptides, microbiome reconditioning). No study of SL-307 is cited on this page at all. The one study cited here used a different strain, CMCC63516, and probiotic results do not carry over from one strain to another.
Spore germination and colonization
Spores are thought to become active cells in the small intestine and then pass through, since Bacillus probiotics do not settle permanently in the gut. What those cells release on the way, and whether any of it matters for how a person feels, was not measured in the one study cited here.
Mechanism of action
Spore-form delivery (heat/acid/bile resistance)
The spore form is generally able to survive stomach acid, bile and heat, and stays stable at room temperature. This is a delivery and storage property of spores in general, not a proven health effect, and it was not tested in the cited study.
Bacitracin antibiotic production
This species can make bacitracin, an antibiotic substance, in laboratory conditions. That is an observation about the bacterium; no study cited here shows it produces an antimicrobial effect in a person's gut.
Microbiota modulation during dysbiosis
One proposed explanation is that the probiotic competes with unwanted bacteria while antibiotics disturb the gut. This is a theory put forward to explain the trial result in children, not something the cited research measured, and the C. difficile use has no citation on this page.
Spore germination + vegetative metabolite production
Spores are believed to become active cells in the small intestine and to pass through rather than take up residence. The substances they may release along the way, and any effect of those substances in people, were not measured in the cited study.
Anti-inflammatory effects
Anti-inflammatory effects are sometimes proposed for spore probiotics, but no study cited on this page measured inflammation, so this remains an untested idea here.
Baseline microbiome interaction (Zhou 2023 finding)
In the 2023 trial letter, how well the probiotic worked appeared to depend on which bacteria a child already carried, with three species linked to a better response. These are correlations from a single small study, so they cannot be used to predict who will respond.
Clinical trials
Double-blind randomized controlled trial in Chinese children, published in 2023 in Clinical and Translational Medicine as a letter, using the CMCC63516 strain (registration ChiCTR-IPR-16009033). This is the only study cited on this page.
Clinical population described in trial publication.
Zhou Q and colleagues, 2023, Clinical and Translational Medicine, published as a letter (doi:10.1002/ctm2.1184; registration ChiCTR-IPR-16009033). Children at several Chinese hospitals received the CMCC63516 strain or a control alongside antibiotics. The headline result was conditional: how much protection the probiotic gave depended on the child's baseline gut bacteria, with P. copri, B. coprocola and B. plebeius linked to a better response. Limitations: small sample, different antibiotics at different hospitals, letter-format reporting rather than a full paper, and children being treated for a medical problem rather than healthy adults.
Refers to hospital research using the probiotic alongside vancomycin in people being treated for Clostridioides difficile infection. No such study is listed in this page's references, so it is background rather than evidence.
Clinical population described in trial publication.
No study is cited on this page for this. It refers to hospital research in patients treated with vancomycin for Clostridioides difficile infection, a serious gut infection that requires medical treatment. With no reference provided, it cannot be counted as evidence for this probiotic, and nothing here describes what the probiotic does for a healthy person.
A review article that counted 68 published papers. A review is not a clinical trial, and this one is not listed in this page's references.
Clinical population described in trial publication.
This is a review article that counted 68 published papers, most of them about the digestive system. A review is not a clinical trial: it summarizes work done by others and tests nothing itself. The review is not listed in this page's references, and it does not show that the probiotic treats enteritis, colitis or diarrhea.